Investigational Drug Information for GB1211
✉ Email this page to a colleague
What is the drug development status for GB1211?
GB1211 is an investigational drug.
There have been 6 clinical trials for GB1211.
The most recent clinical trial was a Phase 1 trial, which was initiated on February 29th 2024.
The most common disease conditions in clinical trials are Non-alcoholic Fatty Liver Disease, Liver Cirrhosis, and Fibrosis. The leading clinical trial sponsors are Galecto Biotech AB, Hoffmann-La Roche, and Linical Europe GmbH.
Summary for GB1211
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 4 |
| WIPO Patent Applications | 3 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 1 (2024-02-29) |
| Vendors | 12 |
Recent Clinical Trials for GB1211
| Title | Sponsor | Phase |
|---|---|---|
| GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma | Galecto Biotech AB | Phase 2 |
| GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma | Providence Cancer Center | Phase 2 |
| GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma | Providence Cancer Center, Earle A. Chiles Research Institute | Phase 2 |
Clinical Trial Summary for GB1211
Top disease conditions for GB1211
Top clinical trial sponsors for GB1211
US Patents for GB1211
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
